BCL2 and acute myeloid leukemia: Here, we demonstrate that the analysis of BCL-2 protein level can be used as a rapid and low-cost method to identify a subgroup of BCL-2− AML patients with high sensitivity to standard IC or HMAs, thereby precluding the need for adding venetoclax treatment in approximately one in five newly diagnosed AML patients.